Titan Pharmaceuticals (TTNP) Competitors $4.99 +0.14 (+2.89%) Closing price 08/15/2025 03:55 PM EasternExtended Trading$5.03 +0.04 (+0.70%) As of 08/15/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. NEUP, CYCC, MRKR, ALVR, AIMD, CTXR, LPTX, NXTC, IXHL, and PRPHShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Neuphoria Therapeutics (NEUP), Cyclacel Pharmaceuticals (CYCC), Marker Therapeutics (MRKR), AlloVir (ALVR), Ainos (AIMD), Citius Pharmaceuticals (CTXR), Leap Therapeutics (LPTX), NextCure (NXTC), Incannex Healthcare (IXHL), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Neuphoria Therapeutics Cyclacel Pharmaceuticals Marker Therapeutics AlloVir Ainos Citius Pharmaceuticals Leap Therapeutics NextCure Incannex Healthcare ProPhase Labs Titan Pharmaceuticals (NASDAQ:TTNP) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders hold more shares of TTNP or NEUP? 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate TTNP or NEUP? Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 159.26%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TTNP or NEUP? In the previous week, Titan Pharmaceuticals had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 4 mentions for Titan Pharmaceuticals and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Titan Pharmaceuticals' score of 0.81 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Titan Pharmaceuticals Positive Neuphoria Therapeutics Very Positive Which has preferable valuation and earnings, TTNP or NEUP? Titan Pharmaceuticals has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan Pharmaceuticals$180K25.23-$4.71M-$4.59-1.09Neuphoria Therapeutics$10K1,522.80-$15.49MN/AN/A Which has more volatility and risk, TTNP or NEUP? Titan Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Is TTNP or NEUP more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -111.53% -96.94% Neuphoria Therapeutics N/A N/A N/A SummaryNeuphoria Therapeutics beats Titan Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.43M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.11%P/E Ratio-1.6920.8931.0825.11Price / Sales25.23364.47466.21115.16Price / CashN/A42.3037.4059.05Price / Book1.878.659.096.18Net Income-$4.71M-$54.65M$3.26B$265.11M7 Day Performance28.11%6.56%7.36%4.21%1 Month Performance5.16%7.53%5.47%2.01%1 Year Performance-1.58%13.69%30.61%23.74% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.4173 of 5 stars$4.99+2.9%N/A-0.6%$4.43M$180K-1.6910News CoverageEarnings ReportUpcoming EarningsShort Interest ↑NEUPNeuphoria Therapeutics2.3131 of 5 stars$7.20-3.1%$21.00+191.7%N/A$13.97M$10K0.00N/APositive NewsCYCCCyclacel Pharmaceuticals1.2693 of 5 stars$9.05+3.1%N/A-97.5%$13.91M$40K-0.0114News CoveragePositive NewsEarnings ReportAnalyst UpgradeMRKRMarker Therapeutics4.0157 of 5 stars$1.19flat$13.17+1,006.4%-60.4%$13.47M$6.59M-0.8960Earnings ReportAnalyst UpgradeShort Interest ↑ALVRAlloVirN/A$2.67-1.5%N/A-86.5%$13.47MN/A-0.13110AIMDAinos0.6076 of 5 stars$3.26+2.5%N/A-1.4%$13.33M$20K-0.5140News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeShort Interest ↑CTXRCitius Pharmaceuticals2.8738 of 5 stars$1.25+1.6%$53.00+4,140.0%-90.9%$13.08MN/A0.0020News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Gap UpLPTXLeap Therapeutics2.4003 of 5 stars$0.31-1.1%$3.38+981.4%-89.1%$13.08MN/A-0.1840News CoverageEarnings ReportShort Interest ↓Gap UpNXTCNextCure4.3248 of 5 stars$4.80-1.4%$25.50+431.3%-72.8%$13.03MN/A-0.1990Short Interest ↑IXHLIncannex Healthcare0.373 of 5 stars$0.45+1.0%N/A-78.8%$13.01M$10K-0.373Short Interest ↑Gap DownPRPHProPhase Labs1.0965 of 5 stars$0.28-9.8%N/A-84.5%$12.97M$6.77M-0.22130Earnings ReportGap Down Related Companies and Tools Related Companies Neuphoria Therapeutics Alternatives Cyclacel Pharmaceuticals Alternatives Marker Therapeutics Alternatives AlloVir Alternatives Ainos Alternatives Citius Pharmaceuticals Alternatives Leap Therapeutics Alternatives NextCure Alternatives Incannex Healthcare Alternatives ProPhase Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access